In January 2010, the European Medicines Agency withdrew its approval for sibutramine and the Food and Drug Administration has restricted its license based on concerns about a raised cardiovascular risk found in the Sibutramine Cardiovascular Outcome Trial (SCOUT) preliminary report.1 2 Despite being contraindicated in poorly controlled hypertension and cardiovascular disease, SCOUT only recruited patients ≥55 years old with known cardiovascular disease or type 2 diabetes plus ≥1 additional risk factor for cardiac disease. Moreover, patients were treated for 5 years, when the recommended period for clinical practice is 12 months. Given the premorbid characteristics of the SCOUT cohort, we …